Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients ; volume:10 ; number:1 ; day:5 ; month:3 ; year:2024 ; pages:1-7 ; date:12.2024
Renal replacement therapy ; 10, Heft 1 (5.3.2024), 1-7, 12.2024
- Urheber
-
Nagano, Nobuo
Ishikawa, Takayuki
Yamaguchi, Masashi
Katsuragi, Yuji
Miya, Masaaki
Tamei, Noriko
Muto, Shigeaki
Tsutsui, Takaaki
Ogawa, Tetsuya
Ito, Kyoko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41100-024-00529-z
- URN
-
urn:nbn:de:101:1-2405101045345.251574225854
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nagano, Nobuo
- Ishikawa, Takayuki
- Yamaguchi, Masashi
- Katsuragi, Yuji
- Miya, Masaaki
- Tamei, Noriko
- Muto, Shigeaki
- Tsutsui, Takaaki
- Ogawa, Tetsuya
- Ito, Kyoko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
The serum vaspin levels are reduced in Japanese chronic hemodialysis patients
Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
The serum vaspin levels are reduced in Japanese chronic hemodialysis patients
Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial
Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients
Hemodialysis patients’ preferences for the management of secondary hyperparathyroidism
Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis
Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
Long-Term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-Label 52-Week Study
Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
First-in-Patient Phase I/II Study of Upacicalcet in Japanese Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: Pharmacokinetic and Pharmacodynamic Properties
Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
Observation of the efficacy of parathyroidectomy for secondary hyperparathyroidism in hemodialysis patients: a retrospective study
The serum vaspin levels are reduced in Japanese chronic hemodialysis patients